Andrew Phillips, MD
Low Vision Rehabilitation · Arcadia, CANPI 1366522427
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,195 of the $1,454 with a category attached, or 82.2%. Alcon accounts for 74.5% of it on its own, with 5 other manufacturers making up the rest. Among low vision rehabilitation clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $41.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Notal Vision, Inc.$240
- Glaukos Corporation$74
- Catalyst Pharmaceuticals, Inc.$20
- Carl Zeiss Meditec AG$19
- Bausch & Lomb, A Division Of Bausch Health US, LLC$17
What the payments were for
- Speaking & faculty fees$24017%
- Food & beverage$1,19582%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 28 | $1,084 |
| Notal Vision, Inc. | 1 | $240 |
| Glaukos Corporation | 3 | $74 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,454 in reported general payments places this provider in the 90th percentile of 37 low vision rehabilitation providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 36 | $16,739 |
| Latanoprost | 549 | $7,936 |
| Brinzolamide | 19 | $5,103 |
| Timolol Maleate | 214 | $4,279 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $4,154 |
| Loteprednol Etabonate | 33 | $4,144 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 150 | $2,996 |
| Brimonidine Tartrate | 115 | $2,875 |
| Prednisolone Acetate | 87 | $2,721 |
| Fluorometholone | 28 | $1,613 |
| Dorzolamide Hcl | 61 | $954 |
| Pilocarpine Hcl | 19 | $953 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 70 | $587 |
| Ketorolac Tromethamine | 37 | $407 |
| Diclofenac Sodium | 21 | $177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AlconSimbrinza | $1,084 | $4,15417 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $17 | $4,14433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 37 low vision rehabilitation providers in California.
Other low vision rehabilitation in Arcadia
- Nina GetzArcadia$329
- Lyly UngSan Francisco$9K
- Joseph LayaRedding$2K
- Shirley HongRowland Heights$2K
- Linda YeeSan Jose$1K
- Grace JengOakland$1K
- Tiffany ChanSan Francisco$1K
- Andy ChenLong Beach$1K
- David ShinFontana$1K
- Leangsok TeaWestminster$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.